Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2022 October;63(5) > The Journal of Cardiovascular Surgery 2022 October;63(5):581-6

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  ENDOVASCULAR TREATMENT OF LONG FEMOROPOPLITEAL DISEASE 

The Journal of Cardiovascular Surgery 2022 October;63(5):581-6

DOI: 10.23736/S0021-9509.22.12374-8

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Bare metal stent in the area of drug eluting devices for long femoropopliteal lesions

Bahaa NASR 1, 2 , Maxime DUBOSQ 3, Yann GOUËFFIC 4

1 Department of Vascular and Endovascular Surgery, Brest University Hospital, Brest, France; 2 INSERM UMR 1101, LaTIM, Brest, France; 3 Aortic Center, Institut Cœur-Poumon, CHU Lille, Lille, France; 4 Department of Vascular and Endovascular Surgery, Paris St. Joseph Hospital, Paris, France



The advancement in the endovascular treatment and the introduction of novel techniques allowed treatment of more complex and longer femoropopliteal lesions. However, the optimal treatment modality is still a source of controversy. The use of bare metal stents (BMS) showed good results for long femoropopliteal lesions. In this review, we summarized all available data on the different treatment strategies of long femoro-popliteal lesions using BMS. Nevertheless, RCTs with head-to-head comparison between BMS strategies are still needed to have more clarification on the best strategy for the endovascular treatment of long femoropopliteal occlusive lesions.


KEY WORDS: Peripheral arterial occlusive disease; Self expandable metallic stents; Endovascular procedures

top of page